 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 08/29/2007 | | | | Major New Study Supports Validity of Statin Drugs Potential For Alzheimer’s Treatment
topic: Statins and Alzheimer's Disease
August 29, 2007: In a new study, scientists reported for the first time finding evidence showing an association between statin use and a lower risk of neuropathologic changes in the brain associated with Alzheimer’s disease (AD). Nymox holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD. |
| 08/21/2007 | | | | Nymox Announces New Clinical Data From BPH Drug Trials To Be Presented at Upcoming U.S. Urology Meeting
topic: R&D: BPH (enlarged prostate) Treatments
August 21, 2007: Nymox today announced that further clinical results from the Company’s studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the meeting of the Western Section of the American Urological Association (AUA) to be held in Scottsdale, Arizona in October. |
| 08/14/2007 | | | | Nymox Reports Second Quarter Financial Results for 2007
topic: Financial
August 14, 2007: Nymox Pharmaceutical Corporation announced today its financial results for the quarter ending June 30, 2007. |
| 07/23/2007 | | | | WallStreet Research Releases Buy Recommendation for Nymox Pharmaceutical Corporation
topic: Financial
July 23, 2007: Nymox announced today that WallStreet Research has released an updated analyst report covering the Company's shares with a speculative buy recommendation. |
| 07/17/2007 | | | | Nymox Announces New Drug Data to Be Presented at Upcoming U.S. Urology Meeting
topic: R&D: BPH (enlarged prostate) Treatments
July 17, 2007: Nymox today announced that further clinical results from the Company’s studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Mid-Atlantic Section of the American Urological Association Meeting in Bermuda in October. |
| 07/03/2007 | | | | Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
topic: R&D: BPH (enlarged prostate) Treatments
July 3, 2007: Nymox today announced that further clinical results from the Company’s studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the New England Section of the American Urological Association Meeting in Boston in September. |
| 06/21/2007 | | | | Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
topic: R&D: BPH (enlarged prostate) Treatments
June 21, 2007: Nymox today announced that detailed results from the Company’s recently completed studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at a series of upcoming U.S. urology meetings, beginning in September at the South Central American Urological Association Meeting in Colorado Springs. |
| 05/17/2007 | | | | NicAlert™ Study in Children to be Presented at American Thoracic Society Conference in San Francisco
topic: Tobacco Exposure Tests
May 17, 2007: Nymox announced today that the results of an important pediatric second-hand smoke study of the Company's NicAlert™ product will be the subject of a podium presentation by Professor Anne Turner Henson of the University of Alabama at the International Conference of the American Thoracic Society in San Francisco on May 20, 2007. The study involved 100 pre-school children who were investigated for second-hand smoke exposure, smokers in the family, and other health issues. |
| 05/15/2007 | | | | Nymox Reports First Quarter 2007 Financial Results
topic: Financial
May 15, 2007: Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2007. |
| 05/07/2007 | | | | Nymox Announces New Positive Results from 3 ˝ Year Study of NX-1207 for Benign Prostatic Hyperplasia
topic: R&D: BPH (enlarged prostate) Treatments
May 7, 2007: Nymox today announced positive results from a new long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company’s two Phase 1-2 studies initiated in 2003. Overall, patients treated with NX-1207 showed a mean improvement of 8.6 points in the primary outcome endpoint of AUA Symptom Score value 42 months after NX-1207 treatment. 50% of these patients reported no additional treatment for the BPH during this period and had a mean improvement of 10.0 points in AUA Symptom Score. |
|